Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 42, 2012 - Issue 12
1,124
Views
25
CrossRef citations to date
0
Altmetric
General Xenobiochemistry

The two enantiomers of tetrahydropalmatine are inhibitors of P-gp, but not inhibitors of MRP1 or BCRP

, , , , , , , , & show all
Pages 1197-1205 | Received 02 May 2012, Accepted 08 Jun 2012, Published online: 19 Aug 2012

References

  • Castro AF, Horton JK, Vanoye CG, Altenberg GA. (1999). Mechanism of inhibition of P-glycoprotein-mediated drug transport by protein kinase C blockers. Biochem Pharmacol 58:1723–1733.
  • Dai CL, Liang YJ, Chen LM, Zhang X, Deng WJ, Su XD, Shi Z, Wu CP, Ashby CR Jr, Akiyama S, Ambudkar SV, Chen ZS, Fu LW. (2009). Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function. Biochem Pharmacol 78:355–364.
  • Fletcher JI, Haber M, Henderson MJ, Norris MD. (2010). ABC transporters in cancer: More than just drug efflux pumps. Nat Rev Cancer 10:147–156.
  • Geick A, Eichelbaum M, Burk O. (2001). Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 276:14581–14587.
  • Glavinas H, Krajcsi P, Cserepes J, Sarkadi B. (2004). The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv 1:27–42.
  • He L, Liu GQ. (2002a). Effects of various principles from Chinese herbal medicine on rhodamine123 accumulation in brain capillary endothelial cells. Acta Pharmacol Sin 23:591–596.
  • He L, Liu GQ. (2002b). Interaction of multidrug resistance reversal agents with P-glycoprotein ATPase activity on blood-brain barrier. Acta Pharmacol Sin 23:423–429.
  • Hong Z, Fan G, Le J, Chai Y, Yin X, Wu Y. (2006). Brain pharmacokinetics and tissue distribution of tetrahydropalmatine enantiomers in rats after oral administration of the racemate. Biopharm Drug Dispos 27:111–117.
  • Hsu B, Kin KC. (1962). Pharmacological study of tetrahydropalmatine and its analogs. A new type of central depressants. Arch Int Pharmacodyn Ther 139:318–327.
  • Huang L, Wang Y, Grimm S. (2006). ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. Drug Metab Dispos 34:738–742.
  • International Transporter Consortium, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V et al. (2010). Membrane transporters in drug development. Nat Rev Drug Discov 9:215–236.
  • Jamroziak K, Robak T. (2004). Pharmacogenomics of MDR1/ABCB1 gene: The influence on risk and clinical outcome of haematological malignancies. Hematology 9:91–105.
  • Jin GZ. (1987). [Progress in studies of the pharmacology of l-tetrahydropalmatine and l-stepholidine]. Yao Xue Xue Bao 22:472–480.
  • Lee JS, Paull K, Alvarez M, Hose C, Monks A, Grever M, Fojo AT, Bates SE. (1994). Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol Pharmacol 46:627–638.
  • Leung WC, Zheng H, Huen M, Law SL, Xue H. (2003). Anxiolytic-like action of orally administered dl-tetrahydropalmatine in elevated plus-maze. Prog Neuropsychopharmacol Biol Psychiatry 27:775–779.
  • Lin MT, Chueh FY, Hsieh MT, Chen CF. (1996). Antihypertensive effects of DL-tetrahydropalmatine: An active principle isolated from Corydalis. Clin Exp Pharmacol Physiol 23:738–742.
  • Lin MT, Wang JJ, Young MS. (2002). The protective effect of dl-tetrahydropalmatine against the development of amygdala kindling seizures in rats. Neurosci Lett 320:113–116.
  • Liu Y, Yu C, Zeng S. (2009). Establishment of Madin-Darby canine kidney cell line with high P-glycoprotein expression. Chin Pharm J 44:1608–1613.
  • Ng TB, Liu F, Wang ZT. (2000). Antioxidative activity of natural products from plants. Life Sci 66:709–723.
  • Nwaozuzu OM, Sellers LA, Barrand MA. (2003). Signalling pathways influencing basal and H(2)O(2)-induced P-glycoprotein expression in endothelial cells derived from the blood-brain barrier. J Neurochem 87:1043–1051.
  • Ottaiano A, De Chiara A, Fazioli F, Talamanca AA, Mori S, Botti G, Milano A, Apice G. (2005). Biological prognostic factors in adult soft tissue sarcomas. Anticancer Res 25:4519–4526.
  • Sha S. (1985). Assay methods for active components in Chinese herb medicines. Beijing: The People’s 11 Medical Publishing House.
  • Shorter D, Kosten TR. (2011). Novel pharmacotherapeutic treatments for cocaine addiction. BMC Med 9:119.
  • Shukla S, Wu CP, Ambudkar SV. (2008). Development of inhibitors of ATP-binding cassette drug transporters: Present status and challenges. Expert Opin Drug Metab Toxicol 4:205–223.
  • Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. (2006). Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5:219–234.
  • Thévenod F, Friedmann JM, Katsen AD, Hauser IA. (2000). Up-regulation of multidrug resistance P-glycoprotein via nuclear factor-κB activation protects kidney proximal tubule cells from cadmium- and reactive oxygen species-induced apoptosis. J Biol Chem 275:1887–1896.
  • von Richter O, Glavinas H, Krajcsi P, Liehner S, Siewert B, Zech K. (2009). A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol 379:11–26.
  • Wang Q, Rager JD, Weinstein K, Kardos PS, Dobson GL, Li J, Hidalgo IJ. (2005). Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. Int J Pharm 288:349–359.
  • Wu CP, Calcagno AM, Ambudkar SV. (2008). Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: Evaluation of current strategies. Curr Mol Pharmacol 1:93–105.
  • Yu J, Piao BK, Pei YX, Qi X, Hua BJ. (2010). Protective effects of tetrahydropalmatine against γ-radiation induced damage to human endothelial cells. Life Sci 87:55–63.
  • Zhao M, Li LP, Sun DL, Sun SY, Huang SD, Zeng S, Jiang HD. (2012). Stereoselective metabolism of tetrahydropalmatine enantiomers in rat liver microsomes. Chirality 24:368–373.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.